MedinCell S.A. Logo

MedinCell S.A.

Develops long-acting injectable therapies using proprietary technology to impact global health.

MEDCL | PA

Overview

Corporate Details

ISIN(s):
FR0004065605
LEI:
969500R79U6PXCL2FF46
Country:
France
Address:
3 RUE DES FRERES LUMIERE, 34830 JACOU
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MedinCell S.A. is a clinical and commercial-stage pharmaceutical company specializing in the development of long-acting injectable (LAI) therapies. Leveraging its proprietary drug delivery technology, the company develops a diverse portfolio of controlled-release products across various therapeutic areas. This innovative approach is designed to enhance treatment efficacy, improve patient compliance, and reduce the overall burden of care by providing sustained therapeutic effects from a single injection. MedinCell collaborates with global pharmaceutical partners to advance its pipeline and address unmet medical needs, with a core mission to impact global health by making treatments more efficient and accessible.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-05 13:46
Earnings Release
Informations privilégiées / Autres communiqués
French 310.2 KB
2025-11-05 13:46
Earnings Release
Inside Information / Other news releases
English 215.5 KB
2025-09-22 07:30
Regulatory Filings
Informations privilégiées / Autres communiqués
French 359.5 KB
2025-09-22 07:30
Regulatory Filings
Inside Information / Other news releases
English 263.8 KB
2025-09-12 07:30
Board/Management Information
Informations privilégiées / Autres communiqués
French 189.0 KB
2025-09-12 07:30
Board/Management Information
Inside Information / Other news releases
English 178.3 KB
2025-09-10 21:41
Regulatory Filings
Informations privilégiées / Autres communiqués
French 171.5 KB
2025-09-10 21:41
Regulatory Filings
Inside Information / Other news releases
English 168.1 KB
2025-06-17 17:45
Annual / Quarterly Financial Statement
Inside Information / News release on accounts, results
English 405.2 KB
2025-06-17 17:45
Earnings Release
Informations privilégiées / Communiqué sur comptes, résultats
French 395.7 KB
2025-06-10 18:00
Report Publication Announcement
Inside Information / Other news releases
English 185.6 KB
2025-06-10 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 192.0 KB
2025-06-06 18:00
Declaration of Voting Results & Voting Rights Announcements
Informations privilégiées / Autres communiqués
French 183.7 KB
2025-05-28 18:00
Report Publication Announcement
Informations privilégiées / Autres communiqués
French 183.1 KB
2025-05-28 18:00
Regulatory Filings
Inside Information / Other news releases
English 156.6 KB

Automate Your Workflow. Get a real-time feed of all MedinCell S.A. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MedinCell S.A.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MedinCell S.A. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-05-02 N/A Other Sell 60,000 600,006.00 EUR

Peer Companies

Xbrane Biopharma Logo
Develops affordable biosimilars for serious diseases using patented, high-yield production tech.
Sweden
XBRANE
Xcell Therapeutics Inc. Logo
Develops serum-free media & automated systems for cell therapy & regenerative medicine.
South Korea
373110
Xencor Inc Logo
Engineering antibody & cytokine therapeutics for cancer and autoimmune diseases via its XmAb platform.
United States of America
XNCR
Xenetic Biosciences, Inc. Logo
Advancing DNase & CAR T immune-oncology platforms to treat hard-to-treat cancers.
United States of America
XBIO
Xenon Pharmaceuticals Inc. Logo
A neuroscience biopharma developing novel therapeutics for epilepsy and depression.
United States of America
XENE
Xeris Biopharma Holdings, Inc. Logo
Develops ready-to-use injectable drugs for chronic, metabolic, and rare diseases.
United States of America
XERS
XORTX Therapeutics Inc. Logo
Developing late-stage, uric acid-lowering therapies for gout and progressive kidney disease.
United States of America
XRTX
Xspray Pharma Logo
Develops improved cancer drugs (PKIs) using patented tech to circumvent secondary patents.
Sweden
XSPRAY
XTL Biopharmaceuticals Ltd. Logo
Acquires and develops late-stage drugs for unmet medical needs, focusing on autoimmune diseases.
Israel
XTLB

Talk to a Data Expert

Have a question? We'll get back to you promptly.